Telcagepant

Last updated
Telcagepant
Telcagepant structure.svg
Telcagepant-3D-balls.png
Clinical data
Routes of
administration 		Oral
ATC code
  • none
Legal status
Legal status
  • Development terminated
Pharmacokinetic data
Elimination half-life 5–8 hours
Identifiers
  • N-[(3R,6S)-6-(2,3-Difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C26H27F5N6O3
Molar mass 566.533 g·mol−1
3D model (JSmol)
  • C1C[C@H](C(=O)N(C[C@@H]1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(NC4=O)N=CC=C5
  • InChI=1S/C26H27F5N6O3/c27-18-4-1-3-17(21(18)28)15-6-7-19(23(38)36(13-15)14-26(29,30)31)33-24(39)35-11-8-16(9-12-35)37-20-5-2-10-32-22(20)34-25(37)40/h1-5,10,15-16,19H,6-9,11-14H2,(H,33,39)(H,32,34,40)/t15-,19-/m1/s1 Yes check.svgY
  • Key:CGDZXLJGHVKVIE-DNVCBOLYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Telcagepant (INN; development code MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co. [1]

In the acute treatment of migraine, it was found to have equal efficacy to rizatriptan [2] and zolmitriptan. [3]

A Phase IIa clinical trial studying telcagepant for the prophylaxis of episodic migraine was stopped on March 26, 2009, after the "identification of two patients with significant elevations in serum transaminases". [4] A memo to study locations stated that telcagepant had preliminarily been reported to increase the hepatic liver enzyme alanine transaminase (ALT) levels in "11 out of 660 randomized (double-blinded) study participants." All study participants were told to stop taking the medication. [5]

In July 2011, Merck announced that it had discontinued development of telcagepant. [6]

See also

References

  1. ↑ Molecule of the Month. February 2009 http://www.prous.com/molecules/default.asp?ID=181.{{cite web}}: Missing or empty |title= (help)[ dead link ]
  2. ↑ Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. (April 2008). "Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine". Neurology. 70 (16): 1304–12. doi:10.1212/01.WNL.0000286940.29755.61. PMID   17914062. S2CID   11612471.
  3. ↑ Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. (December 2008). "Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial". Lancet. 372 (9656): 2115–23. doi:10.1016/S0140-6736(08)61626-8. PMID   19036425. S2CID   43069027.
  4. ↑ Clinical trial number NCT00797667 for "MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine" at ClinicalTrials.gov
  5. ↑ Merck & Co.: Memo to all US study locations involved in protocol MK0974-049
  6. ↑ "Press release: Merck Announces Second Quarter 2011 Financial Results". Merck. July 29, 2011. Archived from the original on April 12, 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.